Cargando…
Nanotherapeutics in transplantation: How do we get to clinical implementation?
Patients undergoing organ transplantation transition from one life‐altering issue (organ dysfunction) to a lifelong commitment—immunosuppression. Regimens of immunosuppressive agents (ISAs) come with significant side effects and comorbidities. Recently, the use of nanoparticles (NPs) as a solution t...
Autores principales: | Plumblee, Leah, Atkinson, Carl, Jaishankar, Dinesh, Scott, Evan, Tietjen, Gregory T., Nadig, Satish N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081154/ https://www.ncbi.nlm.nih.gov/pubmed/35224837 http://dx.doi.org/10.1111/ajt.17012 |
Ejemplares similares
-
Connexins in endothelial cells as a therapeutic target for solid organ transplantation
por: Jaishankar, Dinesh, et al.
Publicado: (2022) -
Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do
por: Sanchez-Torrijos, Yolanda, et al.
Publicado: (2017) -
Extracellular Pyrophosphate in the Kidney: How Does It Get There and What Does It Do
por: Moochhala, Shabbir H.
Publicado: (2012) -
Liver transplantation for hepatocellular carcinoma: Where do we stand?
por: Santopaolo, Francesco, et al.
Publicado: (2019) -
Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?
por: Mikolasevic, Ivana, et al.
Publicado: (2021)